Search company, investor...

Heptares Therapeutics

Founded Year



Corporate Minority | Alive

Total Raised


Last Raised

$5M | 6 yrs ago

About Heptares Therapeutics

Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.

Headquarters Location

BioPark, Broadwater Road Welwyn Garden City

Hertfordshire, AL7 3AX,

United Kingdom

+44 (0)1707 358 628

Missing: Heptares Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Heptares Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Heptares Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Heptares Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Heptares Therapeutics Patents

Heptares Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Piperidines
  • Amines
patents chart

Application Date

Grant Date


Related Topics




Muscarinic antagonists, Piperidines, Amines, Quaternary ammonium compounds, G protein coupled receptors


Application Date


Grant Date



Related Topics

Muscarinic antagonists, Piperidines, Amines, Quaternary ammonium compounds, G protein coupled receptors



Latest Heptares Therapeutics News

Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares

Aug 11, 2022

August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Jonah Comstock delves into what makes this team-up tick. Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own research into promising therapy areas, working with partners who have a good idea but don’t have all the necessary tools to drive it forward. “My group is something of an anomaly within the charity in that the majority of our research funds go out via grants to other bodies to do the actual research,” Nigel Blackburn, director for CRUK’s Centre for Drug Development, told pharmaphorum. “Whereas my group, we are employed and we actually do pro development research ourselves. So I’ve got about 90 staff in total and we have all the functional expertise necessary to take a potential new cancer treatment through lead up, through early phase two, clinical proof of concept, basically. All the assets that we work on are all partnered and come from outside the charity.” Recently CRUK announced a partnership with Tokyo-based biopharma Sosei Heptares to execute a Phase I/IIa clinical trial of HTL0039732, a novel selective EP4 antagonist. For Sosei Heptares, it made sense to work with the group, says Matt Barnes, president of Heptares Therapeutics and head of UK R&D. “We’re not an oncology company,” he told pharmaphorum. “So obviously there is a benefit there to working with a specialist like CRUK. … If we did this on our own, we’d have to completely fund it ourselves and take all the risk rather than share it to some degree, which is what we’re doing. But also, where else would we get this level of expertise and infrastructure in the oncology space?” Bringing immunotherapy to underserved cancer types By specifically blocking a type of prostaglandin receptor called EP4, researchers hope that the treatment can prevent immunosuppression in certain cancers, giving the immune system a better chance to fight them off. While prominent immunotherapies like PD1/L1 checkpoint inhibitors have worked on many common cancer types, others lack strong immunotherapy options. Researchers believe HTL0039732 could provide these benefits to patients with microsatellite stable colorectal cancer, gastroesophageal cancer, and head and neck and castrate resistant prostate cancer. “People with these cancer types have, to date, largely missed out on some of the remarkable advances in the field of immunotherapy,” Blackburn said. “We are therefore thrilled to be partnering with Sosei Heptares to bring their novel immunotherapy candidate into human trials. The hope is that with more trials like this, all cancer patients will eventually be able to benefit from this potentially life-saving form of cancer treatment.” Making a difference In some ways, charities like CRUK fit into the pharma ecosystem in the same way as large and small pharmas, which often partner with biopharmas to develop promising therapies. But the motivation behind their selection process is completely mission-driven. “Our eye is not on a return on investment; our eyes are on patient benefit,” Blackburn said. “So if we feel that by collaborating on the developments of an agent, we can either accelerate the development or broaden the range of indications for which we think it could be licensed, or indeed, in some cases, pick up an agent that’s completely stalled and give it new life, we will apply our resources to it.” In order to find those opportunities, CRUK frequents scientific conferences and scours literature. For their partners, that makes their support valuable beyond the work itself. “CRUK doesn’t just take any assets,” Barnes said. “There is quite a rigorous process that they go through in terms of assessing whether the asset is a suitable standard quality and it’s a good fit for them, and that scientifically the hypothesis makes sense. That’s actually an excellent way to get something like a peer review of our approach and our molecule that we’ve been working on for a few years previously. … It tells us that we pass that kind of quite rigorous threshold.” The importance of partnership Like any drug development group, CRUK experiences a lot of attrition, Blackburn says, with only about 5 percent of the drugs it co-develops making it to market. That’s included some major hits like Temozolomide for brain cancer. And while its investment strategy is based on patient benefit, the charity does take a cut when a drug does well. “We don’t have an eye on ultimate profit market share,” Blackburn said. “But we do think that it’s appropriate the charity should get a share downstream for successful marketed agents. … And that money just gets ploughed straight back into our research funds.” Some projects that Blackburn’s group supports are very hands off, he says, “metaphorically chuck[ing] the asset over the fence and say[ing], take it away, guys, come back when you’ve got some data”. But he feels the strongest partnerships are usually more collaborative – which is how things are shaping up with Heptares. “We’re a professional group, but we bring an academic approach to it,” he said. “And I think that approach combined with the perhaps the more entrepreneurial, less risk-averse approach that you get from biotech, you put those two together and I think you get really good constructive tension between the teams and ultimately some really successful partnerships.”

Heptares Therapeutics Frequently Asked Questions (FAQ)

  • When was Heptares Therapeutics founded?

    Heptares Therapeutics was founded in 2007.

  • Where is Heptares Therapeutics's headquarters?

    Heptares Therapeutics's headquarters is located at BioPark, Broadwater Road, Hertfordshire.

  • What is Heptares Therapeutics's latest funding round?

    Heptares Therapeutics's latest funding round is Corporate Minority.

  • How much did Heptares Therapeutics raise?

    Heptares Therapeutics raised a total of $61.17M.

  • Who are the investors of Heptares Therapeutics?

    Investors of Heptares Therapeutics include Teva Pharmaceuticals, Sosei Heptares, Takeda Ventures, Clarus, Stanley Medical Research Institute and 4 more.

  • Who are Heptares Therapeutics's competitors?

    Competitors of Heptares Therapeutics include Metabolon, Carmot Therapeutics, Visiopharm, DiscoverX, KineMed and 11 more.

Compare Heptares Therapeutics to Competitors


Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation, an area in which it has developed considerable expertise.

Visiopharm Logo

Visiopharm is a provider of quantitative image analysis software and end-to-end Digital Pathology solutions for Hospitals, biopharmaceutical companies, and research institutions around the world. Products include ONCOTOPIX Diagnostics, a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and VirtualDoubleStaining.

Metabolon Logo

Metabolon is a health technology company focused on metabolomics. It offers a tool for precision medicine and life sciences research. The company's platforms and informatics deliver biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.


Novadrug is a drug discovery company geared toward the identification of effective antimicrobial, antiviral, immunosuppressive and anticancer drugs.


Celecure AS does drug discovery and development of anticancer drugs. Celecure is the R&D unit of Celecure Group, an estonian biotech company.


SULFIDRIS, a spin-off of Milan University, is a drug-discovery company. nSULFIDRIS is focused in R&D of drugs (SULFIDRACs) for the treatment of cancer disorders. nSULFIDRACs are multi-modal safe and effective drugs, capable to act on redox-imbalance-related pathogenetic mechanisms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.